Biotech con­sol­i­da­tion con­tin­ues as Nas­daq-list­ed Ery­tech merges with phage ther­a­py de­vel­op­er

Just shy of two decades, the name of Ery­tech Phar­ma — and its mis­sion of us­ing red blood cells to de­liv­er drugs for rare can­cers and or­phan dis­eases — will soon be­come biotech his­to­ry.

The com­pa­ny has been search­ing for strate­gic al­ter­na­tives since its lead drug flunked a Phase III pan­cre­at­ic can­cer tri­al in 2021. And it fi­nal­ly found the per­fect match in fel­low French drug­mak­er Phere­cy­des, which is fo­cused on de­vel­op­ing treat­ments against re­sis­tant bac­te­r­i­al in­fec­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER